Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference
09 nov. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
04 nov. 2021 07h00 HE
|
Passage Bio
On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21Activated multiple clinical sites...
Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
28 oct. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio to Participate in Upcoming October Conferences
27 sept. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS)...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
17 sept. 2021 16h01 HE
|
Passage Bio
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors
07 sept. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference
02 sept. 2021 07h00 HE
|
Passage Bio
PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
27 août 2021 16h01 HE
|
Passage Bio
PHILADELPHIA, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
05 août 2021 07h00 HE
|
Passage Bio
Expanded strategic collaboration with University of Pennsylvania’s Gene Therapy Program to advance genetic medicines for large CNS diseases, initially focused on Alzheimer’s Disease and Temporal Lobe...
Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
04 août 2021 21h00 HE
|
Passage Bio
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...